University of Liverpool Licenses DiscoveryGate® Content Platform

University of Liverpool Licenses DiscoveryGate® Content Platform

San Ramon, CA – November 28, 2006 – Elsevier MDL is pleased to announce that the University of Liverpool has licensed the online DiscoveryGate® content platform. DiscoveryGate serves tens of thousands of eligible users at more than 400 commercial, academic and government institutions worldwide and is supported on both the Microsoft Windows® and Apple Macintosh® OS X platforms. Because DiscoveryGate is widely deployed in the commercial research environment, hands-on experience with DiscoveryGate in the university setting will prepare students for success in today’s highly competitive job market.

"DiscoveryGate enables chemistry researchers, staff and students alike, to access a very useful suite of chemistry databases and links to other scientific information," said David Clay, Deputy Head of Academic Liaison and Finance, University of Liverpool Library. "The ability to access such comprehensive information anywhere on campus will enable researchers to save time locating relevant materials and accelerate decision making."

DiscoveryGate’s unique integration and linking of content enables researchers to compare information and results that are not available through other systems. With the indexing of important new data sources this year (e.g., PharmaPendium™ drug safety resource, PubChem® database, GeneGo systems biology/pathway analysis platform, etc.), DiscoveryGate now provides detailed scientific information on more than 22 million chemical compounds, 11 million reactions and 500 million observed chemical facts, including synthesis, bioactivity, metabolism, toxicology, physical property, chemical sourcing, pharmacology and patent data—all from a single query.

Researchers can access 17 databases including the Beilstein and Gmelin databases (which are also available on the CrossFire system from MDL Information Systems GmbH), MDL® Available Chemicals Directory, MDL® Drug Data Report, MDL® Toxicity Database and authoritative reference works on synthetic methodology. Researchers can also search compounds in PubChem and the Derwent World Patents Index®, and they can link to over 20,000 journal titles (with additional licenses required to access certain third-party content).

"We are very pleased that the University of Liverpool is the first academic institution in the UK to adopt the DiscoveryGate platform," said Dr. Phil McHale, Vice President, Solutions Product Management. "DiscoveryGate is building a solid track record in moving research forward by providing single-click access to a wealth of information that maps to laboratory workflows."

DiscoveryGate for academia features a campus-wide access model. When an institution licenses DiscoveryGate, any number of eligible researchers at the institution may use the service—access is not limited to a few people at a time. To learn more about how DiscoveryGate helps academic researchers find the information they need, visit www.discoverygate.com, contact your Elsevier MDL Account Manager or request information at www.mdl.com.


###

About Elsevier MDL
Elsevier MDL provides informatics, database and workflow solutions that accelerate successful scientific R&D by improving the speed and quality of scientists’ decision making. Researchers around the world depend on Elsevier MDL for innovative and reliable discovery informatics software solutions and services augmented by 400 Elsevier chemistry and life sciences journals and related products. For more information, visit www.mdl.com.

Elsevier is a world-leading publisher of scientific, technical and medical information products and services.

Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange). For more information, visit www.reedelsevier.com.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media Contact
Jean Holt
+1 925 543-5400
j.holt@mdl.com